ABSTRACT To study the prevention of occlusion of aortocoronary-artery bypass grafts, we conducted a prospective, randomized, double-blind trial comparing long-term administration of dipyridamole (begun 2 days before operation) plus aspirin (begun 7 hr after operation) with placebo in 407 patients. Results at 1 month and at 1 year showed a reduction in the rate of graft occlusion in patients receiving dipyridamole and aspirin. On the basis of our clinical trial and our experimental studies in dogs and pigs, we describe four consecutive phases of aortocoronary artery bypass vein-graft disease:
studies are few. There is a wide variation also in occlusion rates, depending on time after operation and risk factors for occlusion.
Early phase of occlusion. Cumulative overall risk of occlusion per distal anastomosis is greatest during the first year and increases more slowly thereafter. The postoperative occlusion rate at one month is 8% to 18%.2-' The occlusion rate per patient, with one or more distal anastomosis occluded, in the same period ranges from 21% to 38%. 27 11 Analysis of risk factors for early occlusion is essential in drug trials, since randomization does not ensure equality of treatment groups, and therapy should be analyzed in subsets at equal risk. In our study,2 two important risk factors that increased the early occlusion rate of bypass grafts were low vein-graft blood flow and a small luminal size of the grafted artery ( 19 and at 10 years is about 50%. 19, 20 In addition, of the grafts patent at 10 years, about 45% have some atherosclerotic narrowing of the lumen. '9' 20 Role of platelets in the pathogenesis of vein-graft disease.
The pathogenesis of vein graft occlusion appears to have some similarities to the development and progres- Role of platelet inhibitor drugs. The decision of when to begin drug therapy, the drugs chosen, and their doses should be based on the capacity of the drugs to forestall the vein-graft occlusive process. Because platelet deposition plays a major role in some of the phases leading to occlusion, platelet inhibitors are preferable to oral anticoagulants because the latter have no significant antiplatelet effects. In addition, use of oral anticoagulants is complicated by the fact that it cannot be started in effective doses until 2 days after operation and must be monitored by laboratory testing. Because platelet deposition begins during operation, therapy for prevention of vein graft occlusion should begin before operation to be fully beneficial.
Platelet inhibitors in the early phases of occlusion. In experiments with dogs, dipyridamole given before, just prior to, and early after operation significantly decreased platelet deposition and formation of mural thrombus early after operation.21 23 Beginning therapy before and immediately after operation probably accounted for the striking benefit in this trial compared with borderline benefit or no benefit in six previous randomized trials where therapy was 
